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A B S T R A C T   
Cardiovascular disease (CVD) is prevalent worldwide and remains a leading cause of death. Although substantial 
progress has been made in the diagnosis and treatment of CVD, the prognosis remains unsatisfactory. Renalase is 
a newly discovered cytokine that is synthesized by the kidney and then secreted into blood. Numerous studies 
have suggested the efficacy of renalase in treating CVD by metabolizing catecholamines in the circulatory system. 
As a new biomarker of heart disease, renalase is normally recognized as a signalling molecule that activates 
cytoprotective intracellular signals to lower blood pressure, protect ischaemic heart muscle and promote 
atherosclerotic plaque stability in CVD, which subsequently improves cardiac function. Due to its important 
regulatory role in the circulatory system, renalase has gradually become a potential target in the treatment of 
CVD. This review summarizes the structure, mechanism and function of renalase in CVD, thereby providing 
preclinical evidence for alternative approaches and new prospects in the development of renalase-related drugs 
against CVD.   
1. Introduction 
Cardiovascular disease (CVD) is a general term for conditions 
affecting the heart or blood vessels and includes hypertension, athero-
sclerosis (AS), coronary artery disease (CAD), coronary microvascular 
dysfunction (CMD), valvular disease, heart failure (HF) and sudden 
cardiac death [1]. Despite improvements in the outcomes of CVD, it is 
one of the main causes of morbidity and mortality [2–5]. Specifically, 
CVD has led to the deaths of more than 18 million people worldwide, 
accounting for approximately 30 % of the global death toll. In particular, 
the CVD-related death rate is approximately 45 % in Europe [6], 
approximately 40 % in China [7], and 23.4 % in the United States [8]. In 
other countries and regions, such as Canada [9] and sub-Saharan Africa 
[10], the total number of deaths is even higher (Fig. 1), and more than 
80 % of deaths in relatively low-income countries are attributable to 
CVD. If the current trend continues, 23.6 million people will have died of 
CVD by 2030. 
Crosstalk occurs between CVD and chronic kidney disease (CKD). 
The pathophysiological relationship between the heart and kidneys is 
complex and bidirectional. Under physiological conditions, the heart 
acts as a pump in the circulatory system to provide continuous blood 
flow and remove carbon dioxide as well as other waste products 
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throughout the body. The kidneys not only remove metabolic waste and 
water from the body and control the balance of specific compounds such 
as sodium, phosphorus and potassium in the blood but also secrete 
hormones, such as renin, erythropoietin and prostaglandin, into the 
blood to regulate blood pressure (BP); moreover, they also promote the 
production of red blood cells. In addition, the heart and kidneys coop-
erate synergistically to regulate the blood supply to human tissues and 
organs. When cardiac or renal dysfunction occurs, the heart and kidneys 
interact with each other through neurohormonal regulatory mecha-
nisms, worsening the condition [11]. A large number of studies have 
indicated that CKD is associated with an increased and more severe risk 
of suffering from cardiac events [12,13], while the mortality rate of 
individuals with CKD is twice that of the general population. Over 50 % 
of deaths in patients with CKD are related to CVD; moreover, CKD pa-
tients are more likely to die from CVD than they are to develop end-stage 
renal disease (ESRD) [14,15]. Furthermore, patients with CKD are 
particularly prone to miss or underappreciate early HF symptoms [16]. 
At present, many biomarkers have been proposed for timely diagnosis 
and prognosis; however, other than natriuretic peptides, none have 
achieved sufficient clinical significance. Therefore, new targets and 
biomarkers must be identified to better determine and further under-
stand CVD and the interaction between CVD and CKD. 
As a new target in CVD and CKD, renalase has shown great potential 
in terms of cardioprotective effects [17]. It is a 
flavin/adenine/dinucleotide-dependent amine oxidase secreted into the 
blood by the kidneys and expressed in the heart, liver, pancreas, skeletal 
muscle and reproductive system [18–21]. Renalase expression is mainly 
related to renal function, renal perfusion and catecholamine expression 
[22]. Previous evidence initially suggested that renalase was involved in 
catecholamine metabolism due to its oxidase activity [17], while spe-
cific single nucleotide polymorphisms (SNPs) in renalase were closely 
associated with an increased risk of developing essential hypertension, 
CKD and CVD [23,24]. However, our understanding of the cellular role 
of renalase is undergoing a paradigm shift due to the available data 
indicating that renalase may function as a cytokine in the human body, 
especially in physiological and pathological cardiac states. In this re-
view, a general overview of these new findings will be provided, with a 
primary focus on the advances and progress in the fields of CVD and CKD 
concurrent with CVD. This work also provides a valuable reference for 
improving the diagnosis, treatment and prognosis of CVD in clinical 
practice. 
2. Structure of renalase 
The renalase gene, located on chromosome 10 of q23.33, contains 9 
exons and spans 309,462 bp (NC_000010.11). Its encoded protein ex-
hibits three major characteristics: less than 20 % similarity to known 
proteins, presence of a signal peptide structure, and absence of a 
transmembrane structure. The structure of renalase includes two mRNA 
variants: transcript variant 1 and transcript variant 2. These variants 
encode putative protein products known as the renalase isoform 1 pre-
cursor (NP_001026879.2) and the renalase isoform 2 precursor 
(NP_060833.1) (sometimes described as hRenalase1 and hRenalase2, 
respectively). At least four alternative splicing isoforms have been 
identified in humans (from hRenalase1 to hRenalase4) [25]. At present, 
seven subtypes of renalase have been identified, with each playing 
different roles in tissues [26]. Of these, hRenalase1 is the most abundant 
subtype in the human body. The dominant mRNA is 1477 nucleotides in 
length and encodes a protein with 342 amino acids and a predicted mass 
of 37.58 kDa. As the subtype with the longest sequence and the main 
form of renalase, hRenalase1 has a conserved structure with homology 
to the amino acid sequence of renalase in chimpanzees (95 % identical) 
and cyanobacteria (20 % identical) [27]. hRenalase2 contains 315 
amino acids with a calculated molecular mass of 34.95 kDa and differs 
from hRenalase1 by one SNP in the first exon, which results in a sub-
stitution of Glu37 → Asp37. Both subtypes include an N-terminal signal 
peptide (amino acids 1–17), a flavin adenine dinucleotide (FAD) binding 
site (amino acids 3–42) and an amino oxidase domain (amino acids 
75–335). Due to the relatively short aminoxin domains, hRenalase1 and 
hRenalase2 are less likely to have monoamine oxidase functions. To 
date, hRenalase3 and hRenalase4 have not yet been adequately studied. 
β-NADH and β-NADPH are considered cosubstrates of renalase [28]; 
both can be oxidized by renalase to produce β-NAD(P)＋ by transferring 
two electrons to the flavin cofactor and converting the configuration of 
ribose C1 from α to β. The chemistry catalysed by renalase is shown in 
Fig. 2 [29,30]. This catalytic activity provides detoxification as well as 
metabolite repair function, and it is also partially inhibited by non-
catalytic isomers or products. 
Fig. 1. Proportion of CVD-related deaths in countries around the world.  
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The tertiary structure of renalase is known and consists of approxi-
mately equal proportions of α and β secondary structures. Nineteen 
residues directly participate in FAD binding, and 6 of these have elec-
trostatic or polar interactions with FAD. The enzyme contains FAD co-
factors, which are mostly buried in extended conformations among the 
proteins, indicating that renalase is a member of the flavin protein su-
perfamily [31]. The three-dimensional structure of renalase is shown in 
Fig. 3. The renalase substrate-binding domain revealed a mode of as-
sociation that was consistent with substrate reactivity. As a secreted 
protein, renalase is different from the monoamine oxidases MAO-A and 
MAO-B in metabolizing catecholamine in cells. It is mainly synthesized 
by renal tubular epithelial cells and secreted in the blood to directly 
metabolize catecholamines. However, Brett et al. claimed that the pu-
tative catecholamine oxidase activity of renalase was determined based 
on flawed methods [32]. 
Understanding and analysing the molecular structure of renalase can 
allow further exploration of its function and mechanism of action. 
Furthermore, it also lays a solid foundation for the development of 
synthetic analogues with potential therapeutic significance in CVD. 
3. Role of renalase in CVD 
Renalase is intensely expressed in the heart as well as the kidneys and 
effectively metabolizes catecholamines using nicotinamide adenine 
dinucleotide as a cofactor [27]. In addition, renalase may also play a 
certain cardioprotective role as a cytokine. Multiple recent observa-
tional studies have shown that renalase was closely associated with 
hypertension, CAD, CMD, HF and AS. All of these effects are described 
and discussed in detail in the following sections. Tables 1 and 2 sum-
marize all of the basic studies and research, while the related effects or 
mechanisms are shown in Fig. 4. 
3.1. Renalase and hypertension 
Hypertension refers to a continuous increase in BP and represents a 
long-term medical disease. Chronic hypertension is a major risk factor 
for CAD, stroke, HF, atrial fibrillation, peripheral arterial disease, and 
CKD [33,34]. Experimental and clinical studies have proven and 
confirmed the relationship between renalase and BP. However, the re-
sults remain ambiguous and require further comprehensive and in-depth 
scientific exploration. 
Renalase plays an important role in the regulation of BP. The rela-
tionship between renalase and BP was confirmed in knockout mice. 
Compared with wild-type mice, renalase knockout mice not only 
showed increased blood catecholamine levels and developed hyperten-
sion symptoms but also exhibited an increased heart rate pressure after 
norepinephrine (NE) perfusion [24]. Xu et al. found that after intrave-
nous injection of recombinant renalase to SD rats, systolic blood pres-
sure (SBP), diastolic blood pressure (DBP) and mean arterial pressure 
(MAP) were significantly reduced, heart rate slowed down, and 
myocardial contractility decreased [17]. Generally, the mechanism by 
which renalase lowers BP can be divided into three aspects. First, it can 
indirectly lower BP by metabolizing catecholamine. Li et al. found that 
lower baseline renalase levels can be intensely activated within a few 
minutes after catecholamine infusion, and then the body degraded cat-
echolamines to inhibit the rapid increase in BP [22]. In addition, data 
collected by Ghosh et al. showed that the decreased expression of 
renalase in rats undergoing subtotal nephrectomy (5/6 Nx) was related 
to the increase in the plasma NE concentration and SBP, suggesting that 
renalase was related to catecholamine metabolism and involved in the 
occurrence of hypertension [35]. Second, BP is regulated by inhibiting 
the activation of the renal dopamine (DA) system [36]. Sizova’s study 
showed a two-fold increase in DA in the urine of renalase knockout mice, 
indicating that renal DA system activity increased after renalase 
knockout and that renalase may be involved in the regulation of renal 
DA system activity [37]. Another study found that the DA D1-like re-
ceptor agonist fenoldopam increased renalase mRNA and protein 
expression in Wistar Kyoto (WKY) rat renal proximal tubule cells. The 
same study further found that renalase was regulated by the D1-like 
receptor mainly via the D5 receptor because silencing of D5 by anti-
sense oligonucleotides blocked the stimulatory effect of the D1-like re-
ceptor on renalase expression in WKY cells. Moreover, inhibition of 
protein kinase C (PKC) blocked the stimulatory effect of fenoldopam on 
renalase expression, while stimulation of PKC increased renalase 
expression, indicating that the stimulatory effect of D1-like receptors on 
renalase expression was mainly mediated by the D5 receptor through the 
PKC pathway in WKY cells and further affected BP [38]. Third, BP can be 
regulated by inhibiting renal sympathetic nerve activity. As Jiang 
Fig. 2. The chemistry catalysed by renalase [30].  
Fig. 3. Three-dimensional structure of renalase [29,31]. (a) Red indicates the FAD binding domain, blue indicates the substrate-binding domain, and green indicates 
the 62–108 subdomain. (b) View of the renalase active-site region (For interpretation of the references to colour in this figure legend, the reader is referred to the web 
version of this article). 
Y. Li et al.                                                                                                                                                                                                                                        
Biomedicine & Pharmacotherapy 131 (2020) 110712
4
Table 1 
Effects of renalase in patients with CVD.  
No. Disease type Treatment groups Location of expression Sample group 
comparison 
Medical effects Reference 
1 Hypertension 
52 hypertensive patients (HT) 
Plasma HT VS Con 
↑24-h ABPM mean SBP [41] 
↑24-h ABPM mean DBP  
↑miRNA 4516 expression  
↓miRNA 145 expression  
No significant difference in renalase 
expression 
51 normotensive controls (Con) 
2 
Primary 
hypertension 
38 adolescents with primary 
hypertension (aged 11  18 years, 
HT) Serum HT VS Con 
↑Renalase [42] 
Positive relationship between serum 
renalase and uric acid and BMI Z-score  50 subjects with normal BP (aged 
11  18 years, Con) 
3 Hypertension 
Hypertensive patients over 65 years 
(range 65  86, HT) 
Plasma HT VS Con 
↑Renalase concentration [43] 
↑DA concentration  
↓DBP  
Advanced abnormalities on 
echocardiography Hypertensive patients below 65 
years (range 19  64, Con) More often suffered from diabetes and 
coronary artery disease 
4 Hypertension 
60 hypertensive patients with no 
CAD (H-Tens, corresponding dose of 
losartan, captopril, atorvastatin, 
aspirin, clopidogrel, nitrocantin, 
metoprolol and carvedilol) 
Serum 
H-Tens VS Con ↑Renalase activity 
[44] 
61 CAD patients with no 
hypertension (CAD, corresponding 
dose of losartan, captopril, 
atorvastatin, aspirin, clopidogrel, 
nitrocantin, metoprolol and 
carvedilol) 
CAD VS Con ↓Renalase activity 
69 nonhypertensive with no CAD 
(Con, lower dose of losartan, 
captopril, atorvastatin, aspirin and 
metoprolol) 
5 Hypertension 
1317 hypertensive people (HT)  
HT VS Con 
↑The frequencies of rs2576178 G allele 
and rs2296545 C allele (0.55 vs 0.49, 
P<0.0001; 0.61 vs 0.55, P<0.0001) 
[49] 
1269 normotensive people (Con) 
6 Preeclampsia (PE) 
40 women aged between 20–39 
years with normotensive pregnancy 
(Normal pregnant) 
Serum 
Normal 
pregnant VS 
Con 
↓Serum uric acid [21] 
↓Serum creatinine  
↓BP  
↑Renalase    
40 women aged between 20–39 
years with newly diagnosed 
preeclampsia (Pregnant with PE) 
Pregnant with 
PE VS Con 
↑BP 
↑Serum uric acid  
↑Proteinuria/24 h  
↓Renalase  
40 nonpregnant control female 
subjects aged between 20–39 years 
(Con) 
Pregnant with 
PE VS Normal 
pregnant 
↑BP 
↑Serum uric acid 
↑Proteinuria/24 h 
↑SGA incidence 
↓Renalase 
↓Gestational age 
↓Birth weight 
7 PE 
179 women with PE (PE) 
Genomic DNA from 
peripheral venous blood 
PE VS Con 
↓Birth weight 
[53] 
↑BP 
↑RNLS rs10887800 GG and rs2576178 
GG 
202 normotensive pregnant women 
(Con) 
8 CAD 
499 Patients with a comorbidity of 
coronary artery disease (CAD) and 
impaired kidney function 
Genomic DNA from patients’ 
peripheral blood  
Genome-wide association study: 
[56] Rs139401390 was significantly 
associated with eGFR (p  0.033) 
9 CHD, HF 
802 patients with HF alone (HF) Renalase gene data of Han 
Chinese individuals in Beijing 
were screened on NCBI and 
HapMap 
HF/CHD VS HF 
Allele A of rs2576178 was significantly 
associated with CAD (p  0.001, OR 
1.625, 95% CI: 1.221  2.160) 
[57] 791 patients with both HF and CHD 
(HF/CHD) 
10 CAD 
449 CAD patients (CAD) Matrix-assisted laser- 
desorption ionization 
(MALDI)/time of flight 
(TOF)-mass spectrometry 
(MS) from venous blood 
samples 
CAD VS Con 
Renalase rs2576178 polymorphism was 
significantly associated with increased 
risk of CAD (GG compared with AA, OR: 
1.60, 95 % CI: 1.07–2.39, P  0.022) 
[58] 
507 healthy controls (Con) 
11 CAD 
CAD patients with 
end-stage renal 
disease (ESRD) 
undergoing HD 
107 patients 
with CAD 
(CAD) 
Genomic DNA from 
peripheral blood 
CAD VS 
CAD 
↓Haemoglobin and albumin level 
↑Frequency of the G allele of rs10887800 
[59] 
polymorphism (0.54 vs 0.47) or 1.34 (95 
% CI: 0.96–1.86), p  0.088 
(continued on next page) 
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Table 1 (continued ) 
No. Disease type Treatment groups Location of expression Sample group 
comparison 
Medical effects Reference 
↓Frequency of the GG genotype [GG vs 
AG  AA], or 1.78 (95 % CI: 1.04–3.03), 
p0.035 
202 patients 
without 
CAD 
(CAD  ) 
12 CAD 
406 Caucasian individuals with a 
history of CAD or myocardial 
infarction or myocardial ischaemia 
participants who had the GG or CG 
genotype of rs2296545 (GG/CG) Genomic DNA from 
peripheral blood 
GG/CG VS CC 
↑Odds of left ventricular hypertrophy (OR 
 1.43; 95 % CI: 0.99–2.06), systolic 
dysfunction (OR  1.72; 95 % CI: 
1.01–2.94), diastolic dysfunction (OR 
1.75; 95 % CI: 1.05–2.93), poor exercise 
capacity (OR  1.61; 95 % CI: 1.05–2.47), 
and inducible ischaemia (OR  1.49, 95 
% CI: 0.99–2.24). 
[60] 
184 Caucasian individuals with a 
history of CAD or myocardial 
infarction or myocardial ischaemia 
participants with the CC genotype of 
rs2296545 (CC) 
13 CAD 
140 healthy subjects (Con) 
Plasma 
CAD VS Con 
↓Renalase 
↑Carotid atherosclerotic plaque and 
[61] 
changes in the ST segment 
CAD patients according to the 
coronary angiography (CAG) 
method: 
normal subgroup without CAG 
abnormality (NS); 
subgroup with one branch with 2S VS NS 
↓Renalase  
stenosis (1S); 
subgroup with two branches with 
stenosis, and a subgroup with 
multiple branches with stenosis 
(2S) 
CAD patients according to the 
Syntax scores: 
LRS VS MRS/ 
HRS 
↑Renalase low-risk subgroup (LRS, 1~22); 
medium-risk subgroup (MRS, 
23~32); 
high-risk subgroup (HRS, 33) MRS VS HRS ↑Renalase 
14 CMD 
14 normal patients (Con) 
Serum 
CMD VS Con 
↑Median renalase (median: 4266 ng/mL; 
IQR 1503; p  0.02) 
[70] 
↑CRP and VEGF 
22 CAD or coronary calcification 
(CALC) patients (CAD/CALC) 
CMD VS CAD/ 
CALC 
Patients with CMD were younger 
↓Mean CFR (mean CFR  1.61 vs. 1.98). 
↑Median renalase (median 4069 ng/mL 
IQR 1850; p  0.004) 
44 CMD patients (CMD) CAD VS CMD ↑VEGF, TNF-a and MMP-9   
Each 1000 ng/mL increase in renalase 
increased the odds of CMD by 34 % 
(adjusted OR: 1.34, 95 % CI: 1.1, 1.7; p 
0.02) 
The addition of renalase improved the C- 
statistic to 0.70 to allow better detection 
of ischaemia (95 % CI: 0.59  0.82) 
15 HF 
75 H F patients: 
27 reduced HF (HFrEF); 
23 mid-range HF (HFmrEF); 
25 HFpEF 
Plasma 
HFrEF VS 
HFmrEF/ 
HFpEF 
Aetiology: 
[74] 
↑Incidence of CAD 
HFrEF (80.8 %), HFmrEF (69.6 %) and 
HFpEF (48 %) 
↑BNP concentration 
↑Renalase 
35 healthy volunteers (Con) HF VS Con 
↑BNP concentration 
↑Renalase 
Biomarkers: 
The renalase concentration was positively 
associated with the left ventricular mass 
index in HFrEF (p  0.029), as well as an 
increased concentration of BNP (p 
0.006) 
16 Ischaemic stroke 
212 ischaemic stroke patients from 
the northern Chinese Han 
population (IS) 
Genomic DNA Con from 
peripheral blood 
IS VS Con 
↑BP 
[79] 
↑BMI 
↑Glucose 
244 healthy controls from the 
northern Chinese Han population 
(Con) 
↑TC 
↑TG 
↑LDL 
↓HDL 
The genotypic distribution (p  0.049) 
and allele frequency (OR  1.55; 95% CI: 
1.095–2.199; p  0.013) of rs10887800 
polymorphism were significantly 
different  
(continued on next page) 
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reported, renal denervation can reduce BP, as it may contribute to the 
suppression of sympathetic nerves and increase the plasma renalase 
content as well as renalase expression in the kidneys [39]. However, 
studies by Wang et al. have shown that phentolamine may inhibit the 
expression of renalase and subsequently lead to increased BP, which was 
in contrast to previously reported findings [40]. The different conclu-
sions may be attributed to the activity of renalase, which might not have 
been detected in the experiments by Wang et al. Additionally, phen-
tolamine truly inhibited the increase in adrenaline-induced renalase 
expression, although whether it also inhibits the expression of renalase 
under alkaline conditions was not determined. Furthermore, the mod-
ulations of biological molecules were much more intricate in vivo than 
in vitro. Previous research was conducted in a proximal renal tubular 
epithelial cell line only, which limited the accuracy of the experimental 
results. 
Most researchers have concluded that renalase expression is 
decreased in hypertensive patients. However, a recent study reported no 
significant difference in renalase between hypertensive patients and 
normotensive control subjects. Notably, miRNA 4516 and miRNA 145 
were found to be independent determinants of essential hypertension, 
with renalase exhibiting a negative correlation with miRNA 4516 and a 
positive correlation with miRNA 145 in hypertensive patients and con-
trols [41]. Another study demonstrated that serum renalase was signif-
icantly higher in hypertensive adolescents than in healthy people and 
correlated with serum uric acid; indeed, patients with elevated serum 
uric acid exhibited significantly higher renalase levels, which remained 
independent of BP [42]. Zbroch et al. assessed the effects of age on 
renalase and catecholamine concentrations in hypertensive patients and 
Table 1 (continued ) 
No. Disease type Treatment groups Location of expression Sample group 
comparison 
Medical effects Reference 
17 AF 
62 patients with paroxysmal AF 
Plasma 
AF VS Con 
↑Renalase (mean 27.99 vs. 21.48 μg/mL, 
p  0.004) 
[80] 
7 patients with persistent AF 
paroxysmal AF 
VS persistent 
AF 
↑Renalase (mean 28.77 vs. 19.05 μg/mL, 
p  0.048) 
15 patients without AF (Con) 
Logistic regression: 
Global four-chamber LA strain was the 
only independent predictor of renalase 
variability; 
Renalase concentration did not predict AF 
recurrence at six-month follow-up (area 
under curve [AUC]  0.614, p  0.216) 
18 Aortic stenosis 
657 patients with aortic stenosis 
(387 men and 270 women) referred 
for aortic valve replacement 
Genomic DNA from 
peripheral blood  
In females: 
[82] 
Asp37 variant of the Glu37Asp 
polymorphism was associated with a 
higher left ventricular mass, 
intraventricular septal thickness and 
posterior wall thickness 
19 CAD 
85 CAD patients with an eGFR <60 
mL/min/1.73 m2 were allocated to 
the CKD () group 
Serum 
CKD () VS 
CKD (  ) 
↑ET-1 
[96] 
↑Renalase 
Patients with both CKD and a high 
renalase level (>the median of 36.2 ng/ 
mL) exhibited the highest serum ET-1 
level 
257 CAD patients with an eGFR 60 
mL/min/1.73 m2 were allocated to 
the CKD (  ) group 
According to multivariate linear 
regression analysis: 
The combination of a high serum renalase 
level with CKD was a significant risk 
factor for an increased serum ET-1 level 
20 CAD 
95 consecutive patients with CAD 
subjected to elective or urgent CA/ 
PCI Urine 
CI-AKI VS non- 
CI-AKI 
↓Urinary renalase-to-creatinine ratio 
[97] 
↓Urinary renalase 
Absolute decrease in renalase below 25 % 
was a predictor of CI-AKI (OR  5.4, 95 % 
CI: 1.3–21.9, P0.027) 9 patients who developed CI-AKI 
21 ESRD 
4 healthy individuals (Con) 
Plasma ESRD VS Con ↓Renalase [17] 
8 patients with ESRD (ESRD) 
22 HD 
50 haemodialyzed patients (HD) 
Serum HD VS Con 
↑Renalase 
[98] 
Renalase was positively correlated with 
serum creatinine and dialysis vintage 
LVMI was positively correlated with 
dialysis vintage and C-reactive protein 
35 healthy controls (Con) 
LVMI was negatively correlated with 
residual diuresis and haemoglobin 
23 
HD＋Heart disease 
Haemodialyzed 
patients 
High renalase level (HR) 
Plasma HR VS LR 
↑miRNA-146a expression 
[99] 
In LR: 
↓miRNA-146a expression 
↑Survival time 
Patients with low miRNA-146a 
expression: Survival time in contrast to 
that of patients with high miRNA-146a 
expression level (median: 69 vs. 56 
months; P  0.430, HR  1.728; 95% CI: 
0.995–3.002) 
Low renalase level (LR) 
24 PD 
40 PD patients 
Serum PD VS Con 
↑Median serum renalase 
[100] 
Renalase was positively correlated with 
C-reactive protein 
40 healthy controls 
Renalase was negatively correlated with 
RRF  
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Table 2 
Effects of renalase on CVD in vivo and in vitro.  
No. Disease type Treatment groups Renalase expression 
location 
Sample group 
comparison 
Medical effects Reference 
1 
Cardiac 
hypertrophy 
SD rats with 5/6 Nx (5/6 Nx) 
Heart 5/6 Nx VS PF/SH 
↑Plasma urea nitrogen 
[35] 
Pair-fed controls (PF) 
↑Serum creatinine 
↑Mean arterial BP 
↑Heart-weight/body-weight ratio 
↑Plasma NE 
SD rats in Sham-operated (SH) 
group 
↑Alpha-1A receptor protein expression 
↓Cardiac beta-1 and beta-2 receptor protein 
expression 
↑GRK2 expression 
↓NE transporter protein 
↓Renalase protein expression 
2 
CKD/ 
hypertension 
H9c2 cells incubated with 20 μmol/ 
L DA for up to 12 h 
Cells  ↑Renalase mRNA (10-fold) 
[22] 
CKD model (5/6 Nx) rats after 
surgery 
Kidneys; heart; 
blood  
↓Blood renalase 
↓Renalase in kidney and heart tissues 
CKD model (5/6 Nx) rats received a 
2-minute infusion of epinephrine, 
NE, or DA at a concentration 
(Model) 
Plasma Model VS Con 
↑Blood prorenalase 
↓Magnitude and duration of activation Normotensive rats infusing 
epinephrine over a 2-minute period 
at doses ranging from 0.1–100 μg/ 
kg (Con) 
3 Hypertension 
Renalase KO mice (KO) 
Kidneys KO VS WT 
KO fed with regular diet, containing 0.9 % Pi: 
[37] 
↓Serum PO4 
↑Urinary PO4  excretion 
WT mice (WT) 
KO mice fed a low-PO4
  diet: 
↓Serum PO4 
↓DA excretion 
↓Urinary excretion in both WT and KO 
KO mice on a regular Pi diet: 
↑Daily urinary excretion of DA 
KO mice maintained on a regular diet:  
↑Daily urinary excretion of DA 
4 Hypertension 
Renal proximal tubules cells from 
Wistar Kyoto rats (WKY) 
Kidneys 
SHR VS WKY ↓Renalase expression 
[38] 
WKY treated with D1-like receptor 
agonist fenoldopam (Fen-W) 
Fen-W VS WKY 
↑Renalase protein and mRNA expression 
↑NADH oxidation 
Fen-W treated with PKC inhibitor 
(Fen-W-I) 
Fen-W-I VS Fen-W 
↓Renalase expression 
(Blocked the stimulatory effect of fenoldopam 
on renalase expression) 
WKY treated with PKC activator 
(WKY-A) 
WKY-A VS Con ↑Renalase expression 
Renal proximal tubule cells from 
spontaneously hypertensive rats 
(SHR) Fen-S VS SHR 
↓Renalase protein and mRNA expression 
↓NADH oxidation 
SHR treated with D1-like receptor 
agonist fenoldopam (Fen-S) 
5 
Spontaneous 
hypertension 
Spontaneous hypertension rats with 
renal denervation 
Plasma, 
kidneys  
Before renal denervation surgery in 
spontaneous hypertension rats: 
↓Plasma renalase content 
↑SBP, DBP and MAP 
[39]  
Before renal denervation surgery in 
spontaneous hypertension rats: 
↑Plasma renalase content 
↑Kidney renalase expression 
↓MAP and tyrosine hydroxylase expression in 
the kidneys 
6 
Myocardial 
hypertrophy 
HK2 cell: preconditioned for 30 min 
with phentolamine or tosyl 
phenylalanyl chloromethyl ketone 
(TPCK) before incubation with 
epinephrine 
Cell culture 
supernatant; 
HK2 cells 
After epinephrine 
treatment 
↑Renalase protein 
↑Renalase mRNA 
[40] 
After phentolamine or 
TPCK treatment 
↓Renalase protein 
↓Renalase Mrna 
7 Hypertension 
Dahl SS rats and SS–13BN male rats: 
Normal salt (0.3 % NaCl) 
BN (13BN normal-salt group); 
SN (SS normal-salt group); 
Kidneys 
SN VS BN 
↑BP 
↑Plasma DA 
↑Plasma DA 
[48] 
Dahl SS rats and SS–13BN male rats: 
High salt (8% NaCl) 
BH (13BN high-salt group); 
SH (SS high-salt group); 
SH VS SN 
↑BP 
↓Renalase gene expression 
↓Renalase protein 
↑Plasma DA 
Dahl SS rats and SS–13BN male rats: 
High salt/potassium (8% NaCl and 
SH VS BH 
(continued on next page) 
Y. Li et al.                                                                                                                                                                                                                                        
Biomedicine & Pharmacotherapy 131 (2020) 110712
8
Table 2 (continued ) 
No. Disease type Treatment groups Renalase expression 
location 
Sample group 
comparison 
Medical effects Reference 
8% KCl) 
BHP (13BN high-salt with 
potassium group) 
SHP (salt-sensitive high-salt with 
potassium group) 
↑BP 
↓Renalase gene expression 
↓Renalase protein 
SHP VS SH ↓BP 
↑Renalase gene expression 
↑Renalase protein 
↓Plasma DA 
8 
Ischaemic 
cardiomyopathy 
Renalase(  /  ) mice (Model)  
Model VS Con 
↑Heart rate 
↑BP 
↑Plasma DA, epinephrine, and NE 
↑SBP and DBP 
↑LV posterior wall thickness 
↓The ratio of NAD/NADH 
↓Plasma and tissue NADH oxidase activities 
[24] 
WT mice 
Model group with myocardial I/R 
(MIR) 
MIR VS Con 
↑Myocardial injury degree 
After assessing recombinant renalase: 
↓Ischaemic myocardial injury area 
9 I/R 
C57BL/6 mice (Con) 
Cardiac muscle Model VS Con 
↑Renalase protein and mRNA expression 
C57BL/6 mice were injected with renalase 
siRNAs and received myocardial I/R surgery: 
↑Ratio of myocardial infarct size/area at risk 
(MI/AAR) 
↓EF and fraction shortening (FS) 
Administration of renalase recombinant 
protein: 
↑MI/AAR 
↑FS 
[63] 
C57BL/6 mice received myocardial 
I/R surgery (Model) 
HCM cells (Con-c) 
Cells Model-c VS Con-c 
↑HIF-1α and 
↑Renalase 
↑Vascular endothelial growth factor α 
↑ Glucose transporter 1 
HCM cells were incubated with HIF-1α 
agonist CoCl2: ↑Renalase mRNA and protein 
levels 
HCM cells were transfected with HIF-1α- 
expressing plasmid: 
↑Renalase mRNA and protein levels 
HCM cells were transfected with HIF-1α 
siRNA: 
↓Renalase mRNA and protein levels 
Model-c group reoxygenation： 
↑Renalase expression 
HCM cells were subjected to 
hypoxia (Model-c) 
C57BL/6 mice were injected with 
HIF-α-siRNAs and received 
myocardial I/R surgery (HIF-α- 
siRNA) 
Cardiac muscle HIF-α- siRNA VS Con 
↑MI/AAR 
Administration of renalase recombinant 
protein: 
↑MI/AAR 
10 CKD 
SD rats: 
Sham-operated group treated with 
tail vein injection of 1.2 mL Hanks’ 
balanced salt solution (Sham) 
Kidneys 
STNx  Ad-β-ga VS 
Sham 
↑SBP 
↑HW/bw and LV weight/bw 
↑LVPWd and LVPWs 
↑LVAWd and LPAWs 
↓LVIDd and LVIDs 
↑Cross-sectional area of cardiomyocytes 
↑Deposition of extracellular matrix 
↓MMP-1 
↑TGF-β and TIMP-1 
↑ERK-1/2 expression in heart and kidneys 
[93] 
SD rats: 
Subtotal nephrectomy group 
treated with tail vein injection of 
1.2  10^10 PFU control adenovirus 
(STNx  Ad-β-gal) 
STNx  Ad-renalase VS 
Sham 
↑SBP 
↑HW/bw and LV weight/bw 
↑LPAWs 
SD rats: 
Subtotal nephrectomy group 
treated with tail vein injection of 
1.2  10^10 PFU adenovirus- 
renalase (STNx  Ad-renalase) 
STNx  Ad-renalase VS 
STNx  Ad-β-ga 
↓SBP 
↓HW/bw and LV weight/bw 
↓LVPWd and LVPWs 
↓LVAWd and LPAWs 
↑LVIDd and LVIDs 
↓Cross-sectional area of cardiomyocytes 
↓Deposition of extracellular matrix 
↑MMP-1 
↓TGF-β and TIMP-1 
↓ERK1/2 expression in heart and kidneys 
11 HF 
Normal rats (Con) 
Kidney Model VS Con 
↓Expression of renalase 
Utilized an isolated perfused rat kidney 
model: 
[75] Unilateral renal artery stenosis rats 
(Model) 
(continued on next page) 
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the possible relationship between these factors and BP or CVD. The re-
sults showed that the elevated levels of renalase in elderly hypertensive 
patients were more closely related to kidney function and CVD than to 
age itself. Therefore, they suggested that renalase appeared to be a 
possible new marker of these indications in this specific population [43]. 
According to Akbari et al., atorvastatin and losartan therapy were 
assumed to be of considerable significance in alleviating hypertension 
by increasing renalase activity [44]. In addition, high salt intake was 
associated with high BP [45], whereas potassium could reverse high 
salt-mediated BP elevation [46,47]. Zheng et al. demonstrated that 
renalase could mediate a salt-induced increase and a potassium-induced 
decrease in BP [48]. Moreover, genetic polymorphisms in renalase were 
also related to hypertension, and by detecting SNPs at specific sites in 
the renalase gene, the risk of hypertension could be predicted. All eight 
selected SNPs in the renalase gene were genotyped and tested in Zhao’s 
study of 2586 Chinese participants, including 1317 hypertensive pa-
tients and 1269 controls. They found that the genotypes rs2576178 GG 
and rs2296545 CC were associated with essential hypertension [49], 
suggesting that patients with these variants were more likely to suffer 
from hypertension. Polymorphisms in the renalase gene appear to confer 
an increased risk of hypertension. 
Additionally, pregnancy-induced hypertension is a unique yet com-
mon complication in pregnant women that affects approximately 5–10% 
of all pregnant women [50]; moreover, preeclampsia (PE) is the leading 
contributor to maternal and neonatal morbidity and mortality world-
wide [51,52]. Yılmaz et al. discovered that the development of PE in 
pregnant women was accompanied by changes in the serum renalase 
level. In this way, low renalase levels partly mediated hypertension and 
kidney damage in PE. Moreover, they found that the renalase level was 
inversely associated with 24-h urinary protein excretion, uric acid and 
haemoglobin levels, which were positively correlated with the glomer-
ular filtration rate (GFR) and birth weight [21]. Through this mecha-
nism, the relationship between renalase and PE provided new 
possibilities for the treatment of PE. The GG genotype and G allele of the 
Table 2 (continued ) 
No. Disease type Treatment groups Renalase expression 
location 
Sample group 
comparison 
Medical effects Reference 
Clearance rate of NE decreased with 
reduction in perfusion flow 
Infarction-induced heart failure rats 
(Model-I) 
Model-I VS Con ↓Flow velocity of renal artery 
↓Renalase expression 
Renalase expression associated with an 
increase in circulating NE 
12 AS 
ApoE  /  mice fed a high-fat diet 
(HF group) 
Abdominal fat; 
brain; kidneys; 
testes; aorta, heart; 
liver; serum 
HF group VS NC group 
↑TC, TG, and LDL-C 
Observed atherosclerotic plaque 
↑ Renalase mRNA expression in abdominal fat 
and brain 
[18] 
C57 mice fed a standard chow diet 
(NC group) 
26-week High-Fat Diet 
group VS NC group 
↑Renalase mRNA expression in kidneys, 
testes, and brain 
↓Renalase mRNA expression in liver 
↓Renalase expression in the cortex and 
medulla of the adrenal glands and liver 
13-week high-fat diet ApoE  /  mice 
treated with valsartan for an 
additional 13 weeks (Valsartan) 
26-week high-fat diet 
ApoE  /  mice VS 13- 
week high-fat diet 
ApoE  /  mice 
Immunohistochemistry: 
Predominant renalase expression in the 
fibrous cap of atherosclerotic plaque in the 
aortae 
↓Renalase expression in the fibrous cap of 
atherosclerotic plaque 
13-week high-fat diet ApoE  /  mice 
treated with simvastatin (positive 
control drug) for an additional 13 
weeks (Simvastatin) 
Valsartan VS Control 
group 
↑Thickness of the fibrous cap of the 
atherosclerotic plaque 
↓Ratio of extracellular lipid to atherosclerotic 
plaque 
↑Expression of Arg-1 and a-actin in the fibrous 
cap of the atherosclerotic plaque 
↑Renalase expression in the serum 
↑Renalase expression in the fibrous cap of 
atherosclerotic plaque 
↓Serum level of TG 
↑ mRNA expression of renalase in liver tissue  
13-week high-fat diet ApoE  /  mice 
treated with distilled water (control 
group) for an additional 13 weeks 
(Control group) 
13 Hypertensive 
Genetically hypertensive BP high 
mice (Hypertensive) 
Kidneys 
Hypertensive VS 
Hypotensive 
Renalase mRNA and protein expression 
[83] 
↑miR-29b 
Common single nucleotide polymorphism in 
human renalase 30-UTR (C/T; rs10749571) 
creates a binding site for miR-146a; 
Genetically hypotensive BP low 
mice (Hypotensive) 
miR-146a downregulated human renalase 30- 
UTR/luciferase activity in that case of the T 
allele, suggesting its potential role in the 
regulation of renalase in humans 
14 
Chronic renal 
disease 
Sham-operated rats that received 
phosphate-buffered saline (PBS) 
subcutaneously (Group I)  Group II VS Group I 
↑ MAP 
[92] 
↑LV/BW ratio 
↑LV hydroxyproline concentration 
↑Plasma creatinine 
↑BUN 
Rats that underwent 5/6 Nx and 
then received PBS daily (Group II) 
↑NE levels 
↓LV papillary muscle developed tension. 
Rats that underwent 5/6 Nx and 
then received recombinant renalase 
daily (Group III) 
Group III VS Group II 
↓MAP 
↓LV/BW ratio 
↓LV hydroxyproline concentration 
↓NE levels 
↑LV papillary muscle developed tension  
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rs10887800 polymorphism might increase BP, and the polymorphism 
might increase susceptibility to PE; however, specific associations have 
not been observed between the RNLS rs10887800 and rs2576178 
polymorphisms and PE. Teimoori et al. suggested that in women from 
Southeast Iran, the combined effect of the rs10887800 GG and 
rs2576178 GG genotypes was associated with an 8.4-fold increase in the 
risk of PE [53]. Of course, those research results were influenced by 
sample size and environmental and ethnic differences. Although a 
meta-analysis showed that the renalase gene rs2296545 polymorphism 
was significantly associated with an increased risk of hypertension, the 
rs2576178 polymorphism may not be correlated with hypertension 
susceptibility [54]. Therefore, whether the genetic polymorphisms in 
renalase are associated with hypertension still needs further 
investigation. 
Thus, current research suggests that increasing the expression of 
renalase can effectively reduce BP. Research on the mechanism of 
renalase has primarily focused on animal experiments; however, most of 
these studies may not be sufficiently in depth, and clinical research 
generally concentrates on the exploration of phenotypes and phenom-
ena. Nevertheless, renalase has great potential as a powerful hypoten-
sive drug, and recombinant or synthetic renalase may represent a new 
method for the treatment of hypertension in the future. 
3.2. Renalase and CAD 
CAD is one of the most common types of heart disease worldwide as 
well as one of the leading causes of death annually. Therefore, the 
specific pathogenesis of CAD continues to be explored. Candidate gene 
approaches and genome-wide association studies have successfully 
identified CAD susceptibility-related genes in the general population 
[55]. To date, several studies have already evaluated the correlation 
between SNPs in the renalase gene and CAD in patients with normal 
renal function. 
Boris et al. collected CAD patients with 50 % stenosis (1 coronary 
artery), and the creatinine-based estimated GFR (eGFR) was estimated 
to be 30  75 ml/min/1.73 m2. In these samples, rs139401390, which is 
located 58.8 kb upstream of renalase, was significantly associated with 
the eGFR at the genome-wide level in patients with CAD presenting 
mildly decreased renal function [56]. The rs2576178 polymorphism was 
found to be involved in CAD risk in Chinese patients by Li et al. [57], and 
allele A of rs2576178 showed potential as a predisposing factor for CAD 
in hypertensive patients. Hu et al. suggested that the GG genotype or G 
allele of the rs2576178 polymorphism contributed to an increased risk 
of CAD [58]. In a case-control study using the PCR-RFLP method to 
genotype 309 haemodialyzed patients (107 with and 202 without CAD), 
two SNPs in the renalase gene (rs10887800 and rs2576178) were gen-
otyped; the most interesting finding was that the rs2576178 poly-
morphism did not influence the risk of CAD, while the rs10887800 
renalase gene polymorphism showed potential involvement in the 
pathogenesis of CAD in haemodialyzed patients [59]. These discrep-
ancies among studies might also be attributed to different geographical 
settings, sample sizes and study designs. Moreover, the variability in 
clinical heterogeneity and polymorphisms among races may also be a 
contributing factor. In a study of 590 Caucasians with stable CAD, the CC 
genotype of the rs2296545 polymorphism was found to be associated 
with left ventricular (LV) hypertrophy, cardiac systolic and diastolic 
Fig. 4. Mechanisms of renalase in CVD.  
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dysfunction, poor exercise capacity and inducible ischaemia [60]. He 
et al. held the opinion that the plasma renalase level could be used to 
indicate the progression of CAD, and changes in renalase might reflect 
the degree of coronary artery stenosis [61]. 
In addition, ischaemic cardiomyopathy is a special type of CAD. Wu 
et al. found that renalase knockout mice showed decreased tolerance to 
cardiac ischaemia, and when exposed to an ischaemic insult, these mice 
developed more severe myocardial necrosis than wild-type mice. These 
authors also found that renalase deficiency was associated with a sig-
nificant decrease in the cellular nicotinamide adenine dinucleotide 
(NAD)/reduced form of nicotinamide adenine dinucleotide (NADH) 
ratio. NAD is important in energy metabolism and electron transfer re-
actions, and it regulates the activity of the NAD-dependent type III 
deacetylase sirtuin1 (SIRT1), which participates in metabolic homeo-
stasis and cell survival pathways [62]. Thus, elevated NAD levels would 
enhance SIRT1 activity, leading to downstream targets such as tran-
scription factors (FOXO1 and FOXO3a) and peroxisome 
proliferator-activated receptor-c coactivator 1a. The decrease in the 
NAD/NADH ratio caused by a lack of renalase would be expected to 
aggravate myocardial damage during ischaemia and impair cardiac 
contractility during reperfusion [24]. 
It has also been reported that renalase could reduce myocardial 
ischaemia/reperfusion (I/R) injury. Du et al. administered a cardiac 
injection of renalase siRNA to specifically downregulate renalase 
expression in the hearts of C57BL/6 mice. The increase in the area of 
myocardial infarction in these mice was accompanied by a decrease in 
the ejection fraction (EF), while the administration of recombinant 
renalase reduced the infarct area and prevented a decrease in EF. 
Furthermore, they identified renalase as a novel target gene of hypoxia- 
inducible factor-1α (HIF-1α), which participates in a new mechanism of 
I/R injury by inducing renalase gene expression. Hence, administration 
of renalase reduced the infarct area and rescued the deterioration of 
cardiac function in myocardial HIF-1α knockdown mice subjected to I/R 
injury. In addition, after recombinant renalase treatment, the level of NE 
decreased in serum, while the levels of NAD  and ATP in the 
myocardium increased, which implied that the cardioprotective effect of 
renalase against I/R might be partly related to its metabolism of cate-
cholamines and regulation of energy [63]. Li et al. also confirmed the 
protective and survival effects of renalase, and they demonstrated that 
renalase protected cardiomyocytes from I/R damage through 
anti-apoptotic and anti-inflammatory mechanisms [64]. According to 
the results of the above study, renalase undoubtedly has a valuable 
function in preventing ischaemic injury of the heart and CAD, providing 
a therapeutic strategy for improving myocardial viability. 
All of these observations prove to some extent the interconnection 
between renalase and CAD. However, based on the relevant current 
literature, the tested polymorphisms may not provide a comprehensive 
view of the genetic variation in renalase. Therefore, further fine- 
mapping studies on renalase and CAD should be performed in the future. 
3.3. Renalase and CMD 
CMD, also known as nonobstructive CAD, presents as a narrowing of 
small blood vessels that branch from the coronary arteries and deliver 
oxygen-rich blood to the myocardium, decreasing the amount of blood 
entering the cardiac muscle and leading to chest pain. In addition, CMD 
is also the most common cause of angina pectoris in non-CAD and ac-
counts for 21–63 % of cases of chest pain in patients with obstructive 
CAD without angiography [65]. Furthermore, CMD mediates ischaemia 
and may cause an increased risk of CVD [66–69]. Therefore, accurate 
and reliable identification of blood biomarkers in CMD patients is 
necessary for clinical diagnosis. 
Safdar et al. analysed blood samples from 14 patients with normal 
haemodynamic parameters as well as 44 patients with CMD and found 
that the renalase level was significantly higher in CMD patients than in 
normal people, supporting the physiological role of renalase in response 
to ischaemia in CMD patients [70]. However, Medvedev et al. performed 
similar research including mass spectrometry (MS) analyses, which did 
not detect the specific prototypic peptide (residues 100–116) of renalase 
in healthy volunteers, although the renalase values determined using 
commercial ELISA kits (45.6  5.4 μg/mL) were even higher than those 
reported in Ref [70]. Moreover, they reported that CMD might differ 
from other pathological conditions depending on the serum renalase 
isoform and suggested that its individual identification as well as 
quantitative analysis might help determine the role of renalase as bio-
markers [71]. 
3.4. Renalase and HF 
HF occurs when an abnormal cardiac structure or function results in 
increased intracardiac pressure or decreased cardiac output, thereby 
leading to the inability of the heart to pump a sufficient volume of blood 
to meet the body’s needs [72]. With increasing morbidity and mortality 
globally, HF also represents a growing health problem [73]. 
Stojanovic et al. collected data from 75 H F participants and 35 
community-based healthy volunteers. A comparison among patients 
with HF, including HF with a mid-range LV ejection fraction (LVEF, 
HFmrEF, 40–49 %) and HF with a preserved LVEF (HFpEF, LVEF  50 
%), showed that the HF patients presented a higher plasma renalase 
concentration than patients in the control group and that this concen-
tration was the highest in patients with a reduced LVEF (LVEF < 40 %). 
These findings suggested that the plasma renalase level could be 
measured to differentiate patients with an LVEF below 40 % and may 
serve as a potent biomarker for identifying HF patients with a reduced 
LVEF. Moreover, they also demonstrated that in patients with a reduced 
LVEF, high plasma renalase concentrations were positively correlated 
with LV hypertrophy and closely related to an increased LV mass index 
[74]. However, the shortcoming of this study was that the plasma 
renalase level was a relatively poor marker for the stratification of pa-
tients with HF compared with the plasma brain natriuretic peptide 
(BNP) level, and the link between renalase and BNP was not explored. In 
the future, multi-marker approaches for HF management should be 
promoted. 
In addition, sympathetic overactivity and catecholamine accumula-
tion are important characteristics in HF. HF can cause kidney ischaemia, 
whereas ischaemic kidneys can decrease the expression of renalase in 
renal tubules. In HF model rats generated via acute myocardial infarc-
tion, renalase expression in renal tissue reached a peak within 1 week 
and then gradually decreased, showing a significant decline in the 4th 
week, which was accompanied by a decrease in renal artery blood flow 
velocity. Moreover, the concentration of renalase in the blood was also 
markedly reduced, while the concentration of catecholamines was 
significantly increased. This suggested that the expression and secretion 
of renalase were reduced, leading to inhibition of sympathetic nerves, 
weakening of the degradation of catecholamines, and subsequent 
participation in the pathological process of HF [75]. 
3.5. Renalase and AS 
AS is the root cause of the majority of CVD cases [76,77]. It is a 
chronic inflammatory disease of the arterial wall arising from an 
imbalance in lipid metabolism and the inflammatory response [78]. 
Our team used apolipoprotein E (ApoE) (-/-) mice fed a high-fat diet 
to examine the tissue distribution of renalase and the effect of valsartan 
on renalase expression. The results showed that ApoE knockout caused a 
dramatic increase in renalase expression in adipose tissue. In lipid 
metabolism disorders caused by a high-fat diet, the expression of rena-
lase is decreased in the liver. Renalase was also expressed in smooth 
muscle cells and M2 macrophages in atherosclerotic plaques, and its 
expression gradually decreased during the transition from stable to 
fragile atherosclerotic plaques. To address this issue, valsartan was used 
as an AT1 receptor antagonist that stabilized atherosclerotic plaques by 
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increasing the serum level of renalase and the expression of renalase in 
the fibrous cap of atherosclerotic plaques. Moreover, valsartan reduced 
serum triglyceride (TG) levels and increased renalase expression in the 
liver. All of these results demonstrated that renalase may be related to 
lipid metabolism and AS and that it may be a possible molecular target 
of valsartan to help stabilize atherosclerotic plaques [18]. In future 
work, our research group will further explore the molecular mechanism 
of renalase in AS to provide a specific theoretical basis for the clinical 
treatment of AS. Additionally, Li et al. have shown that the rs10887800 
SNP in the renalase gene was closely related to severe intracranial ce-
rebral atherosclerotic vascular stenosis in ischaemic stroke patients of 
northern Chinese Han origin [79]. 
Other studies showed that although the expression of renalase could 
not predict sinus rhythm maintenance and did not appear to be useful in 
predicting the recurrence of atrial fibrillation (AF) over a six-month 
observation period, low renalase levels might be related to impaired 
rate control, increased AF burden, and left atrial remodelling progres-
sion in AF patients with pulmonary vein isolation [80]. Therefore, some 
academics believed that renalase has utility as a biomarker of the risk of 
AF and potentially as a marker of disease progression [80,81]. The 
renalase Glu37Asp polymorphism has been reported to be associated 
with LV hypertrophy in females with aortic stenosis. The Glu37Asp 
polymorphism not only leads to amino acid substitutions in the FAD 
binding domain but also may alter the binding affinity of hypoxia- and 
hypertrophy-related transcription factors, thereby ultimately affecting 
renalase expression [82]. Interestingly, regulation of the renalase gene, 
especially at the posttranscriptional level, is emerging as a novel regu-
lator of CVD. Kalyani et al. found that miR-29 and miR-146 participated 
in posttranscriptional regulation of the renalase gene and had implica-
tions in interindividual variations in cardiometabolic traits [83]. 
A large number of studies have concluded that a close relationship 
occurs between renalase and CVD. Therefore, further work is necessary 
to better define the role of renalase in CVD. 
4. Role of renalase in kidney-related CVD 
CKD is defined as a reduced GFR, increased urinary albumin excre-
tion or both, and it is a growing public health issue. Complications 
include increased all-cause and cardiovascular-related mortality, renal 
disease progression and acute kidney injury (AKI) [84]. A close rela-
tionship is observed between renal disease and CVD, and both can 
aggravate each other. People with CKD are known to be at an increased 
risk of CVD due to circulatory alterations caused by renal disease 
[85–88]. Moreover, CVD is the leading cause of death in patients with 
CKD. Future renal function indices should reflect not only the extent of 
kidney injury but also the magnitude of the combined cardiorenal pa-
thology. Circulating renalase could be used as a predictor of mortality 
and adverse renal prognosis in patients with CKD [89] and as a possible 
predictor of kidney-related CVD [90,91]. 
Renalase protects against the development of cardiac hypertrophy 
associated with CKD. Baraka et al. observed a significant increase in 
MAP, LV/body-weight (BW) ratio, LV hydroxyproline concentration, 
and NE levels as well as LV papillary muscle dysfunction in rats un-
dergoing 5/6 nephrectomy (5/6 Nx). Notably, recombinant renalase 
treatment was shown to significantly ameliorate all of the studied pa-
rameters [92]. Additionally, using similar animal models, Yin et al. 
confirmed that renalase could reduce proteinuria, glomerular hyper-
trophy and interstitial fibrosis and significantly reduce fibrosis markers, 
pro-inflammatory cytokines and NADPH oxidase components. Systemic 
delivery of recombinant renalase reduced the development of hyper-
tension, myocardial hypertrophy and myocardial interstitial fibrosis and 
prevented cardiac remodelling by inhibiting the expression of fibrotic 
genes and phosphorylation of ERK-1/2 [93]. Together, these data indi-
cated that renalase shows potential as a therapeutic target for the pre-
vention and treatment of CVD in patients with chronic kidney disease. 
Moreover, an increase in circulating renalase levels has been 
associated with CAD in patients with CKD [94]. Endothelin-1 (ET-1) was 
correlated with endothelial dysfunction as well as vasoconstriction, 
while elevated circulating ET-1 levels were associated with long-term 
CVD-related mortality [95]. A cross-sectional study showed a synergis-
tic effect of serum renalase and CKD on increased serum ET-1 levels in 
342 nondiabetic patients with confirmed CAD. The combination of high 
serum renalase levels and CKD was a significant risk factor for elevated 
serum ET-1 levels, which subsequently increased the danger of coronary 
heart disease [96]. Wybraniec et al. found that the development of 
contrast-induced AKI (CI-AKI) might be related to the urinary renalase 
concentration, which was reduced in the aftermath of coronary 
angiography/percutaneous coronary intervention (CA/PCI) [97]. 
CVD is often complicated by advanced renal disease, and haemo-
dialysis (HD) is one of the most important treatments for renal 
replacement in patients with acute and chronic renal failure. A study 
that included 50 HD patients with heart disease or diabetes and 35 
healthy controls suggested that in patients undergoing HD treatment, 
the LV mass index tended to correlate with the renalase level, which was 
also positively correlated with the serum creatinine level and dialysis 
vintage [98]. Furthermore, it was confirmed that high renalase activity 
yielded a significantly longer survival time in HD patients with heart 
disease [99]. In addition, renalase was associated with C-reactive pro-
tein, and residual renal function acted as a CVD risk factor in peritoneal 
dialysis (PD) patients [100]. Together, these findings strongly suggested 
that renalase prevents acute cardiac injury and mitigates the develop-
ment of cardiac diseases associated with CKD. Renalase may constitute a 
biochemical link in the mutual interplay between renal and cardiac 
pathology. In the future, the potential of renalase as a pathological or 
serological marker of CVD and CKD in patients should be further 
investigated. 
5. Conclusions and future perspectives 
In recent decades, with the continuous changes in social, environ-
mental, medical technology and other factors, the spectrum of CVD and 
the incidence, prognosis and outcome of CVD have changed accordingly. 
At present, the pathogenesis of CVD is constantly under investigation, 
and new diagnostic techniques and biomarkers are continuously being 
applied. CVD prevention and control methods have achieved gratifying 
results, although gaps and shortcomings remain in the process of the 
prevention, diagnosis and treatment of CVD. For example, the number of 
biomarkers for the diagnosis and exclusion of CVD remains small, which 
may lead to some missed diagnoses and delays in treatment opportu-
nities. Therefore, the need to continuously improve the diagnosis and 
treatment of CVD is urgent. 
Experimental results obtained from animal and human studies 
strongly support the notion that renalase, a newly discovered protein 
derived from the kidneys and highly expressed in the kidneys and heart, 
plays a key role in the metabolism of catecholamine and in the protec-
tion of cardiovascular cells. The development of an understanding of the 
structure and function of renalase as well as early clinical studies 
exploring its relationship with different human diseases have identified 
renalase as a substance with potential pathophysiological relevance and 
diagnostic/therapeutic utility. 
Similarly, studies have shown that the injection of recombinant 
renalase could reduce arterial pressure in 5/6 Nx rats and that renalase 
knockout increased susceptibility to cardiac ischaemic damage [35]. 
Moreover, CKD was associated with decreased cardiac renalase expres-
sion, and the lack of renalase may lead to an increased risk of CVD in 
patients with CKD [94,97]. Thus, we speculate that renalase replace-
ment therapy will improve cardiovascular outcomes in CKD. 
However, certain problems remain in the research on renalase. For 
example, some of the contradictions between the ELISA and Western 
blot results might be caused by the low specificity of antibodies in the 
ELISA kit, which represents an important factor that may explain why 
studies exploring the molecular mechanism underlying renalase were 
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limited. Therefore, the development of more standardized and validated 
methods or kits to evaluate the activity and level of renalase in tissue and 
various fluids, including blood and urine, is particularly important. 
Developing a unified standard will lead to more precise, in-depth and 
diverse explorations of renalase. The molecular mechanism of renalase 
in cells must be further explored to identify whether it acts as an 
enzyme, signalling molecule or transcription factor. Moreover, the 
specific regulatory mechanism of the corresponding function needs to be 
identified. At the American Society of Nephrology (ASN) annual meeting 
in 2014, Desir reported that the possible receptor for renalase should be 
PMCA4b, which laid a good foundation for the study of the role of 
renalase-related cytokines [27]. Although current relevant research has 
partially answered this question, the results are not sufficiently in-depth. 
For example, the key cytokines specifically targeted by renalase to exert 
its cardioprotective function during the development of diseases such as 
hypertension, myocardial infarction, coronary heart disease, and HF 
remain unknown. In addition, the drugs, molecules, or targets that can 
regulate the expression of renalase have not been clarified. Although 
Sonawane et al. found that the transcriptional regulators Sp1, STAT3 
and ZBP89 participate in renalase expression and could regulate the 
activity of the renalase promoter [101], these factors have not yet been 
thoroughly explored in CVD. 
All phenotypic studies suggested that renalase is a promising and 
potential drug target. Given the link between CVD and renal disease in 
the endocrine nutriregulation mechanism, renalase has become a drug 
target for CVD. Thus, further work is needed to clarify these observa-
tions and the potential of renalase for development into a new drug to 
effectively treat CVD, and its clinical application merits further atten-
tion. More discoveries and applications are expected in the near future. 
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